SERPINB11 Expression Is Associated With Prognosis of High-grade Serous and Clear Cell Carcinoma of the Ovary
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Soo Jin | - |
dc.contributor.author | Lim, Whasun | - |
dc.contributor.author | Mun, Jaehee | - |
dc.contributor.author | Paik, Haerin | - |
dc.contributor.author | Park, Sunwoo | - |
dc.contributor.author | Lim, Hyunji | - |
dc.contributor.author | Kim, Junhwan | - |
dc.contributor.author | Lee, Eun Ji | - |
dc.contributor.author | Yim, Ga Won | - |
dc.contributor.author | Lee, Nara | - |
dc.contributor.author | Lee, Cheol | - |
dc.contributor.author | Kim, Jae-Weon | - |
dc.contributor.author | Song, Gwonhwa | - |
dc.contributor.author | Kim, Hee Seung | - |
dc.date.accessioned | 2024-06-13T06:30:23Z | - |
dc.date.available | 2024-06-13T06:30:23Z | - |
dc.date.issued | 2021-09 | - |
dc.identifier.issn | 0258-851X | - |
dc.identifier.issn | 1791-7549 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/74158 | - |
dc.description.abstract | Background/Aim: To evaluate the role of serine protease inhibitor B11 (SERPINB11) expression as a prognostic biomarker in high-grade serous carcinoma (HGSC) and clear cell carcinoma of the ovary (CCC). Materials and Methods: We obtained tumor tissues from patients with HGSC (n=145) and CCC (n=59). We evaluated immunohistochemically the expression of SERPINB11 and investigated whether SERPINB11 expression affects platinum-resistance and the prognosis of HGSC and CCC. Results: High expression of SERPINB11 was more common in CCC than in HGSC (57.6% vs. 28.3%; p<0.01), and SEPRINB11 expression did not correlate with platinum-resistance of HGSC and CCC. High expression of SERPINB11 was associated with worse progression-free survival and overall survival with marginal significance in HGSC; no relation between SERPINB11 expression and the prognosis of CCC was found. Conclusion: SERPINB11 expression maybe a prognostic biomarker for HGSC. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | INT INST ANTICANCER RESEARCH | - |
dc.title | SERPINB11 Expression Is Associated With Prognosis of High-grade Serous and Clear Cell Carcinoma of the Ovary | - |
dc.type | Article | - |
dc.identifier.doi | 10.21873/invivo.12547 | - |
dc.identifier.bibliographicCitation | IN VIVO, v.35, no.5, pp 2647 - 2653 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000686259500006 | - |
dc.identifier.scopusid | 2-s2.0-85113842932 | - |
dc.citation.endPage | 2653 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 2647 | - |
dc.citation.title | IN VIVO | - |
dc.citation.volume | 35 | - |
dc.type.docType | Article | - |
dc.publisher.location | 그리이스 | - |
dc.subject.keywordAuthor | High-grade serous | - |
dc.subject.keywordAuthor | clear cell | - |
dc.subject.keywordAuthor | ovarian cancer | - |
dc.subject.keywordAuthor | SERPINB11 | - |
dc.subject.keywordAuthor | prognosis | - |
dc.subject.keywordPlus | PLASMINOGEN-ACTIVATOR INHIBITOR-2 | - |
dc.subject.keywordPlus | POOR-PROGNOSIS | - |
dc.subject.keywordPlus | MASPIN EXPRESSION | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | ENDOMETRIOSIS | - |
dc.subject.keywordPlus | PATHOGENESIS | - |
dc.subject.keywordPlus | MECHANISMS | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | MARKER | - |
dc.subject.keywordPlus | GENE | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.